Shield Therapeutics PLC Rule 2.9 Announcement and TVR Update (8390Y)
May 09 2023 - 11:00AM
UK Regulatory
TIDMSTX
RNS Number : 8390Y
Shield Therapeutics PLC
09 May 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION
FOR IMMEDIATE RELEASE
Shield Therapeutics PLC
("Shield" or the "Company")
Rule 2.9 Announcement and Total Voting Rights Update
Following admission to trading on AIM earlier today of
127,366,565 new ordinary shares of 1.5p each in the capital of the
Company ("Ordinary Shares), which was as a result of the conversion
of US$9,542,019 of the convertible loan between Shield and AOP
Health International Management AG, in accordance with Rule 2.9 of
the City Code on Takeovers and Mergers the Company confirms it has
in issue and admitted to trading on AIM 713,036,342 Ordinary
Shares.
Further, the Company confirms that in accordance with the
requirements of the FCA's Disclosure and Transparency Rule 5.6.1,
the Company's issued share capital consists of 713,036,342 Ordinary
Shares, each with equal voting rights. No shares are held in
treasury.
The above figure may also be used by shareholders of the Company
as the denominator in the calculations by which they will determine
whether they are required to notify their interest, or a change to
their interest, in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
The International Securities Identification Number for Shield's
Ordinary Shares is GB00BYV81293.
Enquiries:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser, Financial
Adviser and Joint Broker
Peel Hunt LLP
James Steel/Miles Cox/Oliver
Duckworth/Edward Beazley +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Fergus Sullivan/Alice
Lane/Nigel Birks +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Accrufer(R)/Feraccru(R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
action compared to other oral iron therapies and has been shown to
be an efficacious and well-tolerated therapy in a range of clinical
trials. More information about Accrufer(R)/ Feraccru(R) , including
the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage pharmaceutical company focused on
the commercialisation of Accrufer(R)/Feraccru(R) (ferric maltol),
an innovative oral iron therapy for iron deficiency differentiated
from other irons by its efficacy, broad label and well-tolerated
formulation . The Group has launched Accrufer(R) in the US with an
exclusive, multi-year collaboration agreement with Viatris, Inc.
Feraccru(R) is commercialised in the UK and European Union by
Norgine B.V., that also have the marketing rights in Australia and
New Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Accrufer(R)/Feraccru(R) in China, Hong Kong,
Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of
Korea, and with KYE Pharmaceuticals Inc. for Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RTTZKLFBXELEBBZ
(END) Dow Jones Newswires
May 09, 2023 11:00 ET (15:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024